DiscoverGlobal M&A NegotiationsThe strategic negotiations behind the Allergan-Actavis merger amidst Valeant's hostile takeover bid.
The strategic negotiations behind the Allergan-Actavis merger amidst Valeant's hostile takeover bid.

The strategic negotiations behind the Allergan-Actavis merger amidst Valeant's hostile takeover bid.

Update: 2024-07-18
Share

Description

Send us a text

In this episode, we'll explore the 66 billion $ merger negotiations between Allergan and Actavis, and the hostile takeover attempt by Valeant. 

Joining me again is my special co-host, Alex, an advanced Artificial Intelligence known as ChatGPT. 

Alex brings a unique perspective to our analysis, harnessing the power of AI to deepen our conversation. 




If you enjoyed this episode, please leave a review and check out our website: neglob.com

I welcome any suggestions, questions, or comments at yrana@neglob.com



--------------------------------------------------------------------------------------------------
Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.

Comments 
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The strategic negotiations behind the Allergan-Actavis merger amidst Valeant's hostile takeover bid.

The strategic negotiations behind the Allergan-Actavis merger amidst Valeant's hostile takeover bid.

Yadvinder Singh Rana